Latest / Charleston News Today | 2 Min News | The Daily News Now!
Daraxonrasib Doubles Pancreatic Cancer Survival | Charleston News
Pancreatic cancer patients are getting a lifeline thanks to daraxonrasib, a breakthrough drug that doubled survival time in trials—from 6.6 to over 13 months. Targeting the KRAS mutation present in 90% of cases, it’s the first direct attack on this long-elusive driver, sparking standing ovations and tears among doctors who’ve seen little progress for decades. Beyond extending life, it may soon enable surgeries or prevent recurrence. Already available via FDA-approved expanded access, this could be the dawn of a new era in fighting one of medicine’s toughest cancers. Listen in comfort:Get a…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.